TI
NRIX icon

Trexquant Investment’s Nurix Therapeutics NRIX Stock Holding History

Trexquant Investment’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
17,645
-192,049
-92% -$3.27M ﹤0.01% 1678
2026
Q1 		$3.25M Buy
209,694
+132,335
+171% +$2.19M 0.02% 824
2025
Q4 		$1.47M Buy
77,359
+62,459
+419% +$897K 0.01% 1078
2025
Q3 		$138K Sell
14,900
-36,633
-71% -$380K ﹤0.01% 1526
2025
Q2 		$587K Buy
+51,533
New +$557K 0.01% 1222
2025
Q1 		– Sell
-22,527
Closed -$424K – 1772
2024
Q4 		$424K Sell
22,527
-136,734
-86% -$3.13M ﹤0.01% 1324
2024
Q3 		$3.58M Sell
159,261
-79,321
-33% -$1.8M 0.05% 608
2024
Q2 		$4.98M Buy
238,582
+25,703
+12% +$400K 0.08% 405
2024
Q1 		$3.13M Buy
212,879
+53,561
+34% +$576K 0.06% 476
2023
Q4 		$1.64M Buy
159,318
+71,252
+81% +$488K 0.04% 622
2023
Q3 		$692K Buy
88,066
+32,212
+58% +$294K 0.02% 889
2023
Q2 		$558K Buy
55,854
+21,107
+61% +$215K 0.01% 963
2023
Q1 		$309K Buy
34,747
+7,697
+28% +$80.2K 0.01% 1188
2022
Q4 		$297K Buy
27,050
+2,064
+8% +$24.9K 0.01% 1110
2022
Q3 		$326K Buy
24,986
+14,636
+141% +$232K 0.01% 992
2022
Q2 		$131K Sell
10,350
-33,978
-77% -$385K 0.01% 1417
2022
Q1 		$621K Buy
44,328
+24,696
+126% +$438K 0.03% 670
2021
Q4 		$568K Buy
+19,632
New +$595K 0.04% 581
2021
Q2 		– Sell
-12,337
Closed -$384K – 1370
2021
Q1 		$384K Buy
+12,337
New +$467K 0.04% 632

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trexquant Investment's NRIX Position: Q2 2026 in Review

Trexquant Investment reduced its Nurix Therapeutics (NRIX) stake by 92% in Q2 2026, selling an estimated $3.27M and leaving 17,645 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Trexquant Investment first reported a position in NRIX in Q1 2021 and has held it in 19 quarters since. The position peaked at $4.98M in Q2 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Trexquant Investment held 17,645 shares of Nurix Therapeutics worth $428K as of Q2 2026.
  • Trexquant Investment sold 192,049 Nurix Therapeutics shares in Q2 2026, an estimated $3.27M.
  • Nurix Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1678 holding.
  • Trexquant Investment first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Trexquant Investment's Nurix Therapeutics position peaked at $4.98M in Q2 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.